Pharmacy Benefits Management Services Home

The ACCF/AHA UA/NSTEMI and STEMI guidelines do not prefer one agent over another. The Committee recognizes that there may be benefits with the newer agents compared to clopidogrel that have been shown in one single, large clinical trial each for both prasugrel and ticagrelor. The recommendations reflect use of the new agents that match subjects ... ................
................